口腔颌面部恶性肿瘤患者血清中透明质酸含量的检测

目的　检测口腔颌面部恶性肿瘤患者血清中透明质酸(HA)的含量,探讨HA对口腔颌面部恶性肿瘤辅助诊断和治疗效果监测的价值。方法　选择住院治疗的口腔颌面部恶性肿瘤患者44例,健康人24例。肿瘤患者于手术前或化疗开始前采血,其中20例患者于手术后或化疗结束后再次采血;24例健康人于常规体检时采血。用放射免疫试验测定所有标本血清中的HA浓度。结果　治疗前口腔颌面部恶性肿瘤患者血清中HA含量显著高于健康人(P<0·05),口腔颌面部鳞癌患者血清中HA含量显著高于健康人(P<0·05),涎腺腺样囊性癌患者血清中HA 含量与健康人无显著差异(P>0·05)。口腔颌面部恶性肿瘤Ⅲ、Ⅳ期患者血清中HA含量显著高于Ⅰ、Ⅱ期患者和健康人(P<0·05)。口腔颌面部恶性肿瘤患者治疗后血清中HA含量低于治疗前,但差异不显著(P>0·05)。结论　HA含量测定对口腔颌面部恶性肿瘤可能有辅助诊断价值。血清中HA的含量变化可作为肿瘤分期和判断肿瘤预后的参考,但不能用于治疗效果的监测。

Examination of Serum Hyaluronic Acid Level in Patients with Oral and Maxillofacial Malignancy

OBJECTIVE: To determine the level of hyaluronic acid (HA) in serum of patients with oral and maxillofacial malignancy and to investigate the correlation between the levels of serum HA and stage of the malignant lesions and treatment response. METHODS: 44 patients with oral and maxillofacial malignancy were analyzed and 24 healthy individuals served as controls. Venous blood was collected from the patients before treatment and the healthy individuals. One week after therapy, venous blood were collected in 24 patients once again. Serum levels of HA were measured with quantitative radioimmunoassay (RIA). RESULTS: Before treatment, the serum HA concentration in patients with oral and maxillofacial malignancy was significantly higher than that of the controls (P < 0.05). Also, the serum HA concentration in patients with OSCC was significantly higher than that of the controls (P < 0.05). No difference was noted in serum HA concentration between patients with salivary ACC and the control group (P > 0.05). The serum HA concentration of patients in stage III and IV was significantly higher than that of patients in stage I and II (P < 0.05). Serum HA levels decreased in patients after a complete treatment, but the difference was not significant (P > 0.05). CONCLUSION: Serum levels of HA may be useful in diagnosis of OSCC and was associated with clinical stages in patients with oral and maxillofacial malignancy. However, it may not be contributory to monitoring treatment response in patients with oral and maxillofacial malignancy.